Insulet Q1 revenue $441.7M (+23% YoY); raises full-year guidance

INSULET CORP

2024-Q1 EPS reported $0.73 revenue$441,700,000

Q1 revenue $441.7M, +23.3% YoY, above guidance of 17-20% constant currency; Omnipod revenue $433.0M.
Net income $51.5M ($0.73 diluted EPS) vs $23.8M ($0.34) prior year; operating margin 12.9% (up 520 bps).
Gross margin 69.5% (up 230 bps); adjusted EBITDA $89.2M (20.2% of revenue) up from 13.6%.
Raised full-year guidance; launched Omnipod 5 with Dexcom G7 in US and with Abbott/Sensor of Choice in Europe.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSULET CORP updated its Full Year 2024 guidance (raised).

Period: Full Year 2024
Guidance: raised
Result: guidance update

Exact text from the filing

Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INSULET CORP reported first quarter ended March 31, 2024 results: revenue 441.7 million, net income 51.5 million, EPS 0.73. Guidance raised.

Period: first quarter ended March 31, 2024
Revenue: 441.7 million
Net income: 51.5 million
EPS: 0.73
Guidance: raised
Result: reported results

Exact text from the filing

First quarter 2024 revenue of $441.7 million, up 23.3%, or 22.8% in constant currency 1 , compared to $358.1 million in the prior year, exceeds the guidance range of 17% to 20% in constant currency due to revenue outperformance for all product lines

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

INSULET CORP filing history →

Source: SEC EDGAR

accession 0001145197-24-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.